Merck Appoints Heads For US And China
This article was originally published in Scrip
Executive Summary
Merck (of Germany) has appointed Gary Zieziula president and managing director of the company's biopharma business in US and Canada and Marc Horn will lead the biopharma business in China as managing director. Zieziula joined Merck in 2014 as chief commercial officer in the US and has previously held senior level positions at Bristol Myers-Squibb, Roche and Amag Pharmaceuticals. Currently Horn is the regional chief financial officer (CFO) of Merck responsible for Eastern Asia for Healthcare, Life Science and Performance Materials. He has over 16 years' finance experience in the pharma and chemicals industry and has held positions at Bayer and Lanxess.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.